HCC comprises∼ 80% of primary liver cancer. HCC is the only major cancer for which death
rates have not improved over the last 10 years. Most patients are diagnosed with advanced …

The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

Background & Aims Metastasis remains the major reason for the high mortality of patients
with hepatocellular carcinoma (HCC). This study was designed to investigate the role of E …

Hepatocellular carcinoma (HCC) accounts for about 90% of all primary liver cancers and is
the second leading cause of cancer-related deaths worldwide. The hypervascular nature of …

Over the past decade, covalent kinase inhibitors (CKI) have seen a resurgence in drug
discovery. Covalency affords a unique set of advantages as well as challenges relative to …

In most cases, sorafenib-resistant HCC cells exhibit significant mesenchymal phenotype and
stemness features. In this context, tumor cells might undergo cell fate transition in response …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer mortality,
accounting for almost 90% of total liver cancer burden. Surgical resection followed by …

Background Hepatocellular carcinoma (HCC) is a common primary malignant tumor which
usually progresses to an advanced stage because of late diagnosis. Sorafenib (Sora) is a …

Human fibroblast growth factor 19 (FGF19, or FGF15 in rodents) plays a central role in
controlling bile acid (BA) synthesis through a negative feedback mechanism. This process …

The poor outcome of patients with non-surgically removable advanced hepatocellular
carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high …